{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:57:48Z","timestamp":1790143068170,"version":"4.0.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Peptides"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.peptides.2023.170943","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:47:56Z","timestamp":1672951676000},"page":"170943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Synergistic interaction between DAMGO-NH2 and NOP01 in peripherally acting antinociception in two mouse models of formalin pain"],"prefix":"10.1016","volume":"161","author":[{"given":"Ning","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.peptides.2023.170943_bib1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ejphar.2013.01.076","article-title":"Opioids, sensory systems and chronic pain","volume":"716","author":"Stein","year":"2013","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/SPC.0000000000000495","article-title":"Opioid analgesia: recent developments","volume":"14","author":"Stein","year":"2020","journal-title":"Curr. Opin. Support Palliat. Care"},{"key":"10.1016\/j.peptides.2023.170943_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/YCO.0000000000000712","article-title":"The opioid overdose crisis as a global health challenge","volume":"34","author":"Krausz","year":"2021","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.peptides.2023.170943_bib4","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41398-019-0625-0","article-title":"The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies","volume":"9","author":"Han","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.peptides.2023.170943_bib5","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00213-021-05791-1","article-title":"Synergistic antihyperalgesic and antinociceptive effects of morphine and methyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate (MP-III-024): a positive allosteric modulator at alpha2GABAA and alpha3GABAA receptors","volume":"238","author":"Rahman","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.peptides.2023.170943_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173544","article-title":"The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence","volume":"886","author":"Iyer","year":"2020","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105322","article-title":"Synergistic interaction between butorphanol and dexmedetomidine in antinociception","volume":"149","author":"Ahsan","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.peptides.2023.170943_bib8","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.3892\/mmr.2017.6174","article-title":"Synergistic antinociceptive effects of alfentanil and propofol in the formalin test","volume":"15","author":"Jia","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.peptides.2023.170943_bib9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1248\/bpb.b20-00230","article-title":"Synergistic antinociceptive activity of tramadol\/acetaminophen combination mediated by mu-opioid receptors","volume":"43","author":"Yoshizawa","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.peptides.2023.170943_bib10","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/j.pain.0000000000001567","article-title":"Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical","volume":"160","author":"Mueller","year":"2019","journal-title":"Pain.: Evid. Analg. Synerg. Opioids Baclofen, Pain."},{"key":"10.1016\/j.peptides.2023.170943_bib11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/pr.114.009209","article-title":"Nociceptin\/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems","volume":"68","author":"Toll","year":"2016","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.peptides.2023.170943_bib12","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/164_2019_214","article-title":"NOP-related mechanisms in pain and analgesia","volume":"254","author":"Toll","year":"2019","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/164_2019_211","article-title":"Effects of NOP-related ligands in nonhuman primates","volume":"254","author":"Kiguchi","year":"2019","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib14","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1111\/bph.12744","article-title":"Functional plasticity of the N\/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists","volume":"171","author":"Schroder","year":"2014","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/bs.apha.2015.10.001","article-title":"Central N\/OFQ-NOP receptor system in pain modulation","volume":"75","author":"Kiguchi","year":"2016","journal-title":"Adv. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/jnr.24624","article-title":"Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse","volume":"100","author":"Kiguchi","year":"2022","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.peptides.2023.170943_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.pain.2004.03.037","article-title":"Evidence for an exclusive antinociceptive effect of nociceptin\/orphanin FQ, an endogenous ligand for the ORL1 receptor, in two animal models of neuropathic pain","volume":"110","author":"Courteix","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.peptides.2023.170943_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.112.194308","article-title":"Roles of mu-opioid receptors and nociceptin\/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates","volume":"343","author":"Cremeans","year":"2012","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.peptides.2023.170943_bib19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.peptides.2017.07.002","article-title":"Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test","volume":"94","author":"Rizzi","year":"2017","journal-title":"Peptides"},{"key":"10.1016\/j.peptides.2023.170943_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/jcpt.12404","article-title":"Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential","volume":"41","author":"Albert-Vartanian","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.peptides.2023.170943_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/FBP.0000000000000558","article-title":"Peripherally acting opioid analgesics and peripherally-induced analgesia","volume":"31","author":"Martinez","year":"2020","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib22","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/jpet.120.000134","article-title":"Strategies for developing kappa opioid receptor agonists for the treatment of pain with fewer side effects","volume":"375","author":"Paton","year":"2020","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.peptides.2023.170943_bib23","first-page":"48","article-title":"Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the mu opioid receptor","volume":"10","author":"Ben Haddou","year":"2014","journal-title":"Mol. Pain."},{"key":"10.1016\/j.peptides.2023.170943_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.brainresbull.2011.10.018","article-title":"The central versus peripheral antinociceptive effects of mu-opioid receptor agonists in the new model of rat visceral pain","volume":"87","author":"Al-Khrasani","year":"2012","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.peptides.2023.170943_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-2999(95)00045-M","article-title":"Peripheral opioid modulation of pain and inflammation in the formalin test","volume":"277","author":"Hong","year":"1995","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2004.01.056","article-title":"Local peripheral effects of mu-opioid receptor agonists in neuropathic pain in rats","volume":"360","author":"Obara","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.peptides.2023.170943_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2021.102212","article-title":"NOP01, a NOP receptor agonist, produced potent and peripherally restricted antinociception in a formalin-induced mouse orofacial pain model","volume":"91","author":"Xiao","year":"2022","journal-title":"Neuropeptides"},{"key":"10.1016\/j.peptides.2023.170943_bib28","article-title":"Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.peptides.2023.170943_bib29","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/bph.13489","article-title":"BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice","volume":"173","author":"Li","year":"2016","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib30","doi-asserted-by":"crossref","first-page":"13394","DOI":"10.1021\/acs.jmedchem.1c00694","article-title":"Development of multifunctional and orally active cyclic peptide agonists of opioid\/neuropeptide FF receptors that produce potent, long-lasting, and peripherally restricted antinociception with diminished side effects","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.peptides.2023.170943_bib31","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ejphar.2017.07.044","article-title":"Peripheral and central sites of action for anti-allodynic activity induced by the bifunctional opioid\/NPFF receptors agonist BN-9 in inflammatory pain model","volume":"813","author":"Zhang","year":"2017","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib32","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.pain.2014.09.033","article-title":"TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor","volume":"155","author":"Chen","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.peptides.2023.170943_bib33","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.pain.2008.08.002","article-title":"Behavioral differentiation between itch and pain in mouse","volume":"139","author":"Shimada","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.peptides.2023.170943_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173169","article-title":"Spinal administration of the multi-functional opioid\/neuropeptide FF agonist BN-9 produced potent antinociception without development of tolerance and opioid-induced hyperalgesia","volume":"880","author":"Zhang","year":"2020","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejphar.2015.08.025","article-title":"Synergistic antinociceptive interaction between palmitoylethanolamide and tramadol in the mouse formalin test","volume":"765","author":"Deciga-Campos","year":"2015","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib36","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.peptides.2023.170943_bib37","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0031-6997(24)01514-X","article-title":"Animal models of nociception","volume":"53","author":"Le Bars","year":"2001","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.peptides.2023.170943_bib38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.neuropharm.2009.12.012","article-title":"Peripheral antinociceptive effects of low doses of naloxone in an in vivo and in vitro model of trigeminal nociception","volume":"58","author":"Capuano","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.peptides.2023.170943_bib39","first-page":"31","article-title":"Opioids","author":"Zollner","year":"2007","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jpain.2014.08.010","article-title":"The fentanyl story","volume":"15","author":"Stanley","year":"2014","journal-title":"J. Pain."},{"key":"10.1016\/j.peptides.2023.170943_bib41","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejphar.2018.06.008","article-title":"Analgesic effects of systemic fentanyl on cancer pain are mediated by not only central but also peripheral opioid receptors in mice","volume":"833","author":"Shinohara","year":"2018","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2018.12.021","article-title":"Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys","volume":"844","author":"Cornelissen","year":"2019","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib43","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/papr.12558","article-title":"Antihyperalgesic, antiallodynic, and antinociceptive effects of cebranopadol, a novel potent nociceptin\/orphanin FQ and opioid receptor agonist, after peripheral and central administration in rodent models of neuropathic pain","volume":"17","author":"Tzschentke","year":"2017","journal-title":"Pain. Pr."},{"key":"10.1016\/j.peptides.2023.170943_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173979","article-title":"The synergistic effects of opioid and neuropeptide B\/W in rat acute inflammatory and neuropathic pain models","volume":"898","author":"Xing","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.peptides.2023.170943_bib45","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1074\/jbc.M109.040634","article-title":"Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation","volume":"285","author":"Evans","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.peptides.2023.170943_bib46","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1471-4159.2004.02921.x","article-title":"Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist","volume":"92","author":"Wang","year":"2005","journal-title":"J. Neurochem"},{"key":"10.1016\/j.peptides.2023.170943_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260880","article-title":"MOP and NOP receptor interaction: Studies with a dual expression system and bivalent peptide ligands","volume":"17","author":"Bird","year":"2022","journal-title":"PloS One"}],"container-title":["Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978123000050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196978123000050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T09:33:23Z","timestamp":1759311203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196978123000050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":47,"alternative-id":["S0196978123000050"],"URL":"https:\/\/doi.org\/10.1016\/j.peptides.2023.170943","relation":{},"ISSN":["0196-9781"],"issn-type":[{"value":"0196-9781","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic interaction between DAMGO-NH2 and NOP01 in peripherally acting antinociception in two mouse models of formalin pain","name":"articletitle","label":"Article Title"},{"value":"Peptides","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.peptides.2023.170943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"170943"}}